Xcout IntelCellCure
CellCure Neurosciences is an Israeli biotechnology company developing cell-based therapies derived from pluripotent stem cells, notably retinal pigment epithelium cells for treating retinal diseases such as geographic atrophy associated with dry age-related macular degeneration. Its intended customers and beneficiaries include ophthalmology researchers, clinical partners, and patients with degenerative retinal conditions.
Subscribe to see CellCure’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
CellCure at a glance
CellCure is a biotechnology company headquartered in Israel. Its most recent funding round, Seed, raised $3M in March 2006.
CellCure funding rounds
Every round on record:
| Date | Round | Amount | Investors |
|---|---|---|---|
| Seed | $3M | — |
Who invested in each round, lead investors, valuations and the co-investor graph — open the full funding history →
CellCure competitors
A few of CellCure's closest competitors — see the full list of competitors and alternatives →
Neurotech Pharmaceuticals is a biotechnology company that develops transformative therapies for chronic eye diseases, utilizing its proprietary Encapsulated Cell Therapy platform. The company serves patients with conditions such as Macular Telangiectasia Type 2 by providing advanced treatments designed to protect against progressive vision loss.
Matricelf Ltd, a biotechnology company, develops a platform for autologous tissue engineering for various medical conditions. The company’s regenerative medicine platform intends to cure a range of medical conditions, including spinal cord injuries, age-related macular degeneration, Parkinson’s disease, and myocardial infarction, as well as for 3D bioprinting. The company has a strategic collaboration with Sheba Medical Center for the development and clinical advancement of its neural tissue implant product for the treatment of spinal cord injury. The company has a strategic collaboration with CiRA Foundation for the development of regenerative manufacturing technologies and the evaluation of iPSC-based neural tissue engineering for therapeutic applications. The company was incorporated in 2019 and is based in Ness Ziona, Israel.
Healios K.K., a Tokyo-based biopharmaceutical firm established in 2011, specializes in the discovery, development, manufacturing, and commercialization of advanced cell and regenerative medical therapies. The company operates across key markets including Japan, Europe, and the United States. Its robust pipeline features several cellular and tissue-based products, such as HLCR011 and HLCR012, which are induced pluripotent stem cell (iPSC)-derived regenerative medicines aimed at treating age-related macular degeneration. Another iPSC-based therapy, HLCL041, is being developed for metabolic liver disease. Furthermore, Healios is progressing HLCM051, a regenerative treatment designed for ischemic stroke and acute respiratory distress syndrome, alongside HLCN061 for solid tumor indications. The company also maintains a joint research partnership with Hyogo Medical University, focusing on eNK cell-based cancer immunotherapies to combat mesothelioma. Healios K.K. adopted its current name in September 2013, having previously operated under the name Retina Institute Japan, K.K.
Acucela is a biotechnology company developing ophthalmic therapeutics for retinal diseases, including age-related macular degeneration and Stargardt disease. Its research has included visual-cycle modulators such as emixustat, aimed at treating degenerative eye conditions.
Character Biosciences is a biotechnology company that uses human genetics and functional genomics to discover and develop precision medicines. Its work has focused particularly on genetically informed therapies for age-related diseases, including ophthalmic conditions such as age-related macular degeneration.
Aurion Biotech Inc. develops regenerative cell therapies for ophthalmology, focusing on treatments for corneal endothelial disease and vision loss. Its lead product, AURN001, is a combination therapy utilizing human corneal endothelial cells designed to restore corneal clarity and provide a minimally invasive alternative to traditional donor tissue transplantation. The company serves patients suffering from blindness and provides advanced treatment options for ophthalmologists.
Get CellCure's news by email
Funding rounds, acquisitions, new executives, launches and expansions, each with a two-line summary and a link to the source. One short email a day, only when there is news.
Free: up to 5 companies, daily. Subscribers also follow whole sectors and saved filters (M&A in Israel, AI funding…), get instant alerts, in-app notifications and signed webhooks, and open the full profile behind every name. Subscribe →
Share this card
Post the link and the card appears automatically — each network fetches the image itself.
More on CellCure in Xcout Intel
- 1 funding round with the investors in each, and who they co-invest with
- The full competitor set, tracking, exports and API access